scholarly journals Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

Diabetes Care ◽  
2020 ◽  
Vol 43 (4) ◽  
pp. 710-718 ◽  
Author(s):  
Paola Maffi ◽  
Torbjörn Lundgren ◽  
Gunnar Tufveson ◽  
Ehab Rafael ◽  
James A.M. Shaw ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Secretion ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Controlled Trial ◽  
Pancreatic Islet Transplantation ◽  
Phase 3 ◽  
Double Blind

scholarly journals Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus

2010 ◽  
Vol 6 (5) ◽  
pp. 274-284 ◽  
Author(s):  
Amy Hughes ◽  
Claire Jessup ◽  
Chris Drogemuller ◽  
Daisy Mohanasundaram ◽  
Clyde Milner ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gene Therapy ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation

scholarly journals Reduction in Carotid Intima-Media Thickness After Pancreatic Islet Transplantation in Patients With Type 1 Diabetes

Diabetes Care ◽  
2012 ◽  
Vol 36 (2) ◽  
pp. 450-456 ◽  
Author(s):  
K. K. Danielson ◽  
B. Hatipoglu ◽  
K. Kinzer ◽  
B. Kaplan ◽  
J. Martellotto ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Pancreatic Islet Transplantation ◽  
Media Thickness

First Brazilian pancreatic islet transplantation in a patient with type 1 diabetes mellitus

2004 ◽  
Vol 36 (4) ◽  
pp. 1117-1118 ◽  
Author(s):  
F.G Eliaschewitz ◽  
C.A.M Aita ◽  
T Genzini ◽  
I.L Noronha ◽  
F.H Lojudice ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation

scholarly journals Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-22 ◽  
Author(s):  
Nadine E. Rekittke ◽  
Meidjie Ang ◽  
Divya Rawat ◽  
Rahul Khatri ◽  
Thomas Linn
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Graft Function ◽  
Individual Therapy ◽  
Regenerative Therapy ◽  
Pancreatic Islet Transplantation

Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy.

Sign in / Sign up

Export Citation Format

Share Document